Cargando…
Peripheral blood RNA biomarkers for cardiovascular disease from bench to bedside: a position paper from the EU-CardioRNA COST action CA17129
Despite significant advances in the diagnosis and treatment of cardiovascular diseases, recent calls have emphasized the unmet need to improve precision-based approaches in cardiovascular disease. Although some studies provide preliminary evidence of the diagnostic and prognostic potential of circul...
Autores principales: | Vanhaverbeke, Maarten, Attard, Ritienne, Bartekova, Monika, Ben-Aicha, Soumaya, Brandenburger, Timo, de Gonzalo-Calvo, David, Emanueli, Costanza, Farrugia, Rosienne, Grillari, Johannes, Hackl, Matthias, Kalocayova, Barbora, Martelli, Fabio, Scholz, Markus, Wettinger, Stephanie Bezzina, Devaux, Yvan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9799060/ https://www.ncbi.nlm.nih.gov/pubmed/34648023 http://dx.doi.org/10.1093/cvr/cvab327 |
Ejemplares similares
-
Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129
por: Gomes, Clarissa Pedrosa da Costa, et al.
Publicado: (2019) -
A Year in the Life of the EU-CardioRNA COST Action: CA17129 Catalysing Transcriptomics Research in Cardiovascular Disease
por: Robinson, Emma Louise, et al.
Publicado: (2020) -
Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129
por: Badimon, Lina, et al.
Publicado: (2021) -
The impact of passive and active smoking on inflammation, lipid profile and the risk of myocardial infarction
por: Attard, Ritienne, et al.
Publicado: (2017) -
Consensus guidelines for the validation of qRT-PCR assays in clinical research by the CardioRNA consortium
por: de Gonzalo-Calvo, David, et al.
Publicado: (2022)